Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Feb 15, 2019; 11(2): 102-116
Published online Feb 15, 2019. doi: 10.4251/wjgo.v11.i2.102
Published online Feb 15, 2019. doi: 10.4251/wjgo.v11.i2.102
EUROPAC criteria | |
Criterion 1 | ≥ 2 first-degree relatives with pancreatic cancer |
Criterion 2 | ≥ 3 relatives with pancreatic cancer |
Criterion 3 | Possible associated cancer syndrome (defined as sub-criteria below) in addition to the case of pancreatic cancer being studied |
Criterion 3.a: BRCA1/2 | Personal/family history (≥ 1 first/second-degree relatives) of breast/ovarian cancer |
Criterion 3.b: Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome | Personal/family history of melanoma in ≥ 1 first/second degree relative AND a high total body naevi count (often > 50) |
Criterion 3.c: Lynch syndrome | Personal/family history (≥ 1 first/second-degree relatives) of a Lynch syndrome-associated cancer (such as colorectal, endometrial, small bowel, renal) |
Criterion 3.d: Peutz-Jeghers syndrome | Oral/mucous membrane pigmentation +/- a personal/family history (≥ 1 first/second-degree relatives) of gastrointestinal cancers in first/second degree relatives |
- Citation: Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O’Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019; 11(2): 102-116
- URL: https://www.wjgnet.com/1948-5204/full/v11/i2/102.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i2.102